The Regents of the University of California

United States of America

Back to Profile

Receive daily alerts for new
USPTO trademarks filed by this owner
1-100 of 7,920 for The Regents of the University of California Sort by
Query
Patent
United States - USPTO
Aggregations Reset Report
Date
New (last 4 weeks) 86
2021 January (MTD) 51
2020 December 77
2020 November 73
2020 October 104
See more
IPC Class
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons 337
A61K 9/00 - Medicinal preparations characterised by special physical form 312
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids 289
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca 235
A61K 39/00 - Medicinal preparations containing antigens or antibodies 232
See more
Status
Pending 2,026
Registered / In Force 5,894
Found results for  patents
  1     2     3     ...     80        Next Page

1.

METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION

      
Application Number 16639514
Status Pending
Filing Date 2018-08-31
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Kisseleva, Tatiana
  • Brenner, David
  • Xu, Jun

Abstract

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for reducing addiction to alcohol, and for ameliorating, reversing, treating or preventing Alcoholic Liver Disease (ALD), or alcohol-induced brain injury, wherein optionally the alcohol-induced brain injury comprises neuronal death and astrogliosis (reducing alcohol-induced neuronal death and astrogliosis). In alternative embodiments, provided methods for administering to the individual in need thereof a compound or composition capable of inhibiting or decreasing the expression or activity of an IL-17 or IL-17 receptor (IL-17R) or RORγt protein, transcript and/or gene to treat or for use in: reducing addiction to alcohol; or ameliorating, reversing, treating or preventing Alcoholic Liver Disease (ALD) or alcohol-induced brain injury; or, inhibiting ROR γt to effectively block production of IL-17 cytokines and attenuate development of alcohol-induced liver fibrosis and brain damage.

IPC Classes  ?

  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61P 25/32 - Alcohol-abuse
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

2.

LITHIUM-EXCESS TRANSITION-METAL-DEFICIENT SPINELS FOR FAST CHARGING/DISCHARGING LITHIUM-ION BATTERY MATERIALS

      
Application Number 16928743
Status Pending
Filing Date 2020-07-14
First Publication Date 2021-01-21
Owner The Regents of University of California (USA)
Inventor
  • Ceder, Gerbrand
  • Ji, Huiwen

Abstract

Li-ion battery materials, such as Li-ion cathodes, are provided that have spinels characterized by a close-packed face-centered-cubic rocksalt-type structure and spinel-like ordered TM (the TM preferably occupying one of the two octahedral sites 16c and 16d) that favor fast Li transport kinetics. Such spinels have a larger deviation from a normal spinel and have a formula. Li1+xTM2-yO4-zFz where 0.2≤x≤1, 0.2≤y≤0.6, and 0≤z≤0.8; and TM is Mn, Ni, Co, Al, Sc, Ti, Zr, Mg, Nb, or a mixture thereof. The spinels achieve a higher gravimetric energy density than traditional spinels while still retaining high capacity at an extremely fast charging/discharging rate.

IPC Classes  ?

  • H01M 4/134 - Electrodes based on metals, Si or alloys
  • H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids
  • H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
  • H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
  • H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
  • C01G 45/12 - Manganates; Permanganates

3.

NONRECIPROCAL AND RECONFIGURABLE PHASED-ARRAY ANTENNAS

      
Application Number 16931281
Status Pending
Filing Date 2020-07-16
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Gómez-Diaz, Juan Sebastián
  • Álvarez-Melcón, Alejandro
  • Zang, Jiawei

Abstract

A nonreciprocal phased-array antenna includes an array of resonant antennas a1, . . . , an. During transmission, an outbound signal having a frequency f0 and a phase shift φdi caused by propagation through a data network feeds into each resonant antenna ai. Each resonant antenna a, upconverts the outbound signal using a modulation signal having a frequency fm and a phase shift φmi caused by propagation through a modulation network to produce an upconverted radiated signal having a frequency f0+fm and a phase proportionate to φdi+φmi. During reception, an inbound signal of frequency f0+fm is received at each resonant antenna ai and is downconverted using the modulation signal to produce a downconverted signal having a frequency f0 and a phase proportionate to −φmi. After passing through the data network to the inbound port, the downconverted signal has a phase proportionate to φdi−φmi.

IPC Classes  ?

  • H01Q 3/36 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the phase by electrical means with variable phase-shifters
  • H01Q 21/29 - Combinations of different interacting antenna units for giving a desired directional characteristic

4.

ENGINEERED B LYMPHOCYTES AND COMPOSITIONS HAVING MICRO-RNA AND METHODS FOR MAKING AND USING THEM

      
Application Number 16866055
Status Pending
Filing Date 2020-05-04
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor Zanetti, Maurizio

Abstract

Provided are engineered B lymphocytes modified to express one or several different types of microRNAs or anti-miRs where in one embodiments the lymphocytes contain multiple copy numbers of nucleic acids encoding the one or several different types of miRs or anti-miRs. Provided are compositions and methods for treating, ameliorating, or preventing a cancer cell, a breast cancer cell or a triple negative breast cancer, or a breast cancer cell that tests negative for estrogen receptors, progesterone receptors, or HER2, comprising or by administering a composition, formulation or pharmaceutical composition comprising a microRNA or anti-miR. Provided are methods for treating an inflammation, a disease, a condition, infection or cancer capable of being treated by modulation or inhibition or expression of an miRNA or anti-miRs by administering to an individual in need thereof a B lymphocyte that secretes a microRNA or anti-miR, or a B lymphocyte supernatant, extracellular vesicle or exosome having a microRNA or anti-miR.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K 9/127 - Liposomes
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • A61P 35/00 - Antineoplastic agents
  • C12N 5/0781 - B cells; Progenitors thereof
  • A61K 9/51 - Nanocapsules
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

5.

RAPID AND PRECISE TOOL EXCHANGE MECHANISM FOR INTRAOCULAR ROBOTIC SURGICAL SYSTEMS

      
Application Number 16982506
Status Pending
Filing Date 2019-03-20
First Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Tsao, Tsu-Chin
  • Gerber, Matthew

Abstract

A system for intraocular robotic surgery includes: (1) a set of mounts to receive a tool collar to which a surgical tool is secured; (2) a rotational actuator connected to the set of mounts to drive rotation of the set of mounts; and (3) a translational actuator connected to the set of mounts to drive linear translation of the set of mounts.

IPC Classes  ?

  • A61B 34/00 - Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
  • A61B 34/35 - Surgical robots for telesurgery
  • A61B 34/37 - Master-slave robots
  • B25J 5/00 - Manipulators mounted on wheels or on carriages

6.

DEVICE AND METHOD FOR FORCE PHENOTYPING OF CELLS FOR HIGH-THROUGHPUT SCREENING AND ANALYSIS

      
Application Number 17033488
Status Pending
Filing Date 2020-09-25
First Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Di Carlo, Dino
  • Tseng, Peter
  • Pushkarsky, Ivan

Abstract

A system for assaying forces applied by cells includes an optically transparent substrate comprising a soft material having a Young's modulus within the range of about 3 kPa to about 100 kPa. An array of molecular patterns is disposed on a surface of the optically transparent substrate, the molecular patterns include fluorophore-conjugated patterns adherent to cells. The system includes at least one light source configured to excite the fluorophore-conjugated patterns and an imaging device configured to capture fluorescent light emitted from the fluorophore-conjugated patterns. Dimensional changes in the size of the patterns are used to determine contractile forces imparted by cells located on the patterns.

IPC Classes  ?

  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N 21/64 - Fluorescence; Phosphorescence
  • G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • G01N 33/487 - Physical analysis of biological material of liquid biological material

7.

SEMANTIC INTERIOR MAPOLOGY: A TOOL BOX FOR INDOOR SCENE DESCRIPTION FROM ARCHITECTURAL FLOOR PLANS

      
Application Number 16932438
Status Pending
Filing Date 2020-07-17
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Trinh, Viet
  • Manduchi, Roberto

Abstract

A computer implemented method or system including a map conversion toolkit and a map Population toolkit. The map conversion toolkit allows one to quickly trace the layout of a floor plan, generating a file (e.g., GeoJSON file) that can be rendered in two dimensions (2D) or three dimensions (3D) using web tools such as Mapbox. The map population toolkit takes the scan (e.g., 3D scan) of a room in the building (taken from an RGB-D camera), and, through a semi- automatic process, generates individual objects, which are correctly dimensioned and positioned in the (e.g., GeoJSON) representation of the building. In another example, a computer implemented method for diagraming a space comprises obtaining a layout of the space; and annotating or decorating the layout with meaningful labels that are translatable to glanceable visual signals or audio signals.

IPC Classes  ?

  • G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
  • G06T 17/20 - Wire-frame description, e.g. polygonalisation or tessellation

8.

SYSTEM AND METHOD FOR OPTIMIZING HYDROCARBON PRODUCTION FROM SUBSURFACE RESERVOIRS

      
Application Number 16516016
Status Pending
Filing Date 2019-07-18
First Publication Date 2021-01-21
Owner
  • Chevron U.S.A. Inc. (USA)
  • The Regents of the University of California (USA)
Inventor
  • Hoversten, Gary Michael
  • Commer, Michael

Abstract

A method is described for subsurface hydrocarbon reservoir characterization including receiving a time-lapse electromagnetic (EM) dataset and a flow dataset; inverting the time-lapse EM dataset using a parametric inversion that models steel well casings to determine a volume of fluid-changed reservoir; inverting the time-lapse EM dataset and the flow dataset using a joint inversion that honors the volume of the fluid-changed reservoir to determine relative permeability and capillary pressure; and characterizing flow characteristics in the volume of the fluid-changed reservoir. The method may be executed by a computer system.

IPC Classes  ?

  • G01V 3/38 - Processing data, e.g. for analysis, for interpretation or for correction
  • G01V 3/30 - Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination or deviation specially adapted for well-logging operating with electromagnetic waves
  • E21B 49/00 - Testing the nature of borehole walls; Formation testing; Methods or apparatus for obtaining samples of soil or well fluids, specially adapted to earth drilling or wells
  • E21B 41/00 - Equipment or details not covered by groups

9.

MIXED SIGNAL NEUROMORPHIC COMPUTING WITH NONVOLATILE MEMORY DEVICES

      
Application Number 16608006
Status Pending
Filing Date 2018-04-27
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Strukov, Dmitri
  • Bayat, Farnood Merrikh
  • Bavandpour, Mohammad
  • Mahmoodi, Mohammad Reza
  • Guo, Xinjie

Abstract

Building blocks for implementing Vector-by-Matrix Multiplication (VMM) are implemented with analog circuitry including non-volatile memory devices (flash transistors) and using in-memory computation. In one example, improved performance and more accurate VMM is achieved in arrays including multi-gate flash transistors when computation uses a control gate or the combination of control gate and word line (instead of using the word line alone). In another example, very fast weight programming of the arrays is achieved using a novel programming protocol. In yet another example, higher density and faster array programming is achieved when the gate(s) responsible for erasing devices, or the source line, are re-routed across different rows, e.g., in a zigzag form. In yet another embodiment a neural network is provided with nonlinear synaptic weights implemented with nonvolatile memory devices.

IPC Classes  ?

  • G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
  • G06N 3/04 - Architecture, e.g. interconnection topology
  • G11C 16/04 - Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS

10.

Multi-Spectral THz Micro-Doppler Radar Based on Silicon-Based Picosecond Pulse Radiators

      
Application Number 16931936
Status Pending
Filing Date 2020-07-17
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Babakhani, Aydin
  • Razavian, Seyedmohammadreza
  • Assefzadeh, Mahdi
  • Hosseini, Mostafa

Abstract

Systems and methods for modulation and demodulation using a micro-Doppler effect are described. In an embodiment, the method includes radiating, using a picosecond pulse generator with an antenna, a train of THz pulses that form a frequency comb, where the frequency comb is reflected from an object such that the frequency several tones in the frequency comb are shifted based on the speed of the object and demodulating the reflected frequency comb to recover a THz Doppler signature of the object.

IPC Classes  ?

  • G01S 13/50 - Systems of measurement based on relative movement of target
  • G01S 7/28 - RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES - Details of systems according to groups , , of systems according to group - Details of pulse systems

11.

VAN DER WAALS INTEGRATION APPROACH FOR MATERIAL INTEGRATION AND DEVICE FABRICATION

      
Application Number 16982477
Status Pending
Filing Date 2019-03-19
First Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Duan, Xiangfeng
  • Huang, Yu
  • Liu, Yuan

Abstract

An electronic or optoelectronic device includes: (1) a layer of a first material; and (2) a layer of a second material disposed on the layer of the first material, wherein the first material is different from the second material, and the layer of the first material is spaced from the layer of the second material by a gap.

IPC Classes  ?

  • H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions
  • H01L 51/05 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for rectifying, amplifying, oscillating or switching and having at least one potential-jump barrier or surface barrier; Capacitors or resistors with at least one potential-jump barrier or surface barrier
  • H01L 29/786 - Thin-film transistors
  • H01L 29/66 - Types of semiconductor device

12.

BAMBAM: PARALLEL COMPARATIVE ANALYSIS OF HIGH-THROUGHPUT SEQUENCING DATA

      
Application Number 17025525
Status Pending
Filing Date 2020-09-18
First Publication Date 2021-01-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Sanborn, John Zachary
  • Haussler, David

Abstract

The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treatment regime. The methods may also be used to evaluate protein and/or metabolite levels that correlate with such clinical conditions. The methods are also of use to ascertain the probability outcome for a patient's particular prognosis.

IPC Classes  ?

  • G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G06F 40/169 - Annotation, e.g. comment data or footnotes
  • G06F 3/0484 - Interaction techniques based on graphical user interfaces [GUI] for the control of specific functions or operations, e.g. selecting or manipulating an object or an image, setting a parameter value or selecting a range
  • G06T 11/20 - Drawing from basic elements, e.g. lines or circles
  • G06N 7/00 - Computer systems based on specific mathematical models
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

13.

VIRTUAL TILE ROUTING FOR NAVIGATING COMPLEX TRANSIT HUBS

      
Application Number 16932301
Status Pending
Filing Date 2020-07-17
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Lam, Jonathan
  • Mirzaei, Fatemeh
  • Manduchi, Roberto

Abstract

A computer implemented method or system for creating a route for navigating a transit hub or plaza using an application executing on a user's mobile device. The application accesses a tessellated map comprising first tiles each including a different area of interest on the map; and second tiles including a walkable area connecting the different areas of interest. The application highlights one of the first tiles including one of the different areas of interest selected using input from the user; highlights one of the second tiles including a location of the mobile device on the map; and highlights a series of the second tiles linking the location to the one of the areas of interest. A method of creating the tessellated map is also disclosed.

IPC Classes  ?

  • G01C 21/34 - Route searching; Route guidance
  • G01C 21/36 - Input/output arrangements for on-board computers
  • G01C 21/28 - Navigation; Navigational instruments not provided for in groups specially adapted for navigation in a road network with correlation of data from several navigational instruments

14.

COMPOSITIONS FOR EXPANDING REGULATORY T CELLS (TREG), AND TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES AND CONDITIONS

      
Application Number 16989816
Status Pending
Filing Date 2020-08-10
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor Franco, Alessandra

Abstract

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and method for making and using them. Provided are immunotherapies for promoting expansion of natural, Treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; as immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (IVIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or Juvenile Idiopathic Arthritis; a neoplastic hematological disorder, or a leukemia.

IPC Classes  ?

  • C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 9/127 - Liposomes
  • A61K 9/14 - Particulate form, e.g. powders

15.

IMPROVED PEPPER PLANTS

      
Application Number 17042467
Status Pending
Filing Date 2019-03-29
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Van Deynze, Allen E.
  • Hill, Theresa A.

Abstract

The present invention provides methods of preparing a cultivated pepper plant bearing fruit having a low destemming force, as well as methods of preparing a cultivated pepper plant bearing clustered fruit. The invention also provides cultivated pepper plants prepared by these methods.

IPC Classes  ?

16.

DIGITAL WATERMARKING OF MACHINE LEARNING MODELS

      
Application Number 17042773
Status Pending
Filing Date 2019-03-21
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Rouhani, Bita Darvish
  • Chen, Huili
  • Koushanfar, Farinaz

Abstract

A method may include embedding, in a hidden layer and/or an output layer of a first machine learning model, a first digital watermark. The first digital watermark may correspond to input samples altering the low probabilistic regions of an activation map associated with the hidden layer of the first machine learning model. Alternatively, the first digital watermark may correspond to input samples rarely encountered by the first machine learning model. The first digital watermark may be embedded in the first machine learning model by at least training, based on training data including the input samples, the first machine learning model. A second machine learning model may be determined to be a duplicate of the first machine learning model based on a comparison of the first digital watermark embedded in the first machine learning model and a second digital watermark extracted from the second machine learning model.

IPC Classes  ?

  • G06N 3/04 - Architecture, e.g. interconnection topology
  • G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
  • G06N 7/00 - Computer systems based on specific mathematical models
  • G06F 21/16 - Program or content traceability, e.g. by watermarking

17.

CASZ COMPOSITIONS AND METHODS OF USE

      
Application Number 17032521
Status Pending
Filing Date 2020-09-25
First Publication Date 2021-01-21
Owner The Regents of the University of California (USA)
Inventor
  • Doudna, Jennifer A.
  • Burstein, David
  • Chen, Janice S.
  • Harrington, Lucas B.
  • Paez-Espino, David
  • Banfield, Jillian F.

Abstract

Provided are compositions and methods that include one or more of: (1) a “CasZ” protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a “CasZ trancRNA”), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

18.

SHORT CONJUGATED OLIGOELECTROLYTES AND USES THEREOF

      
Application Number 17040320
Status Pending
Filing Date 2019-03-21
First Publication Date 2021-01-21
Owner The Regents Of The University Of California (USA)
Inventor
  • Bazan, Guillermo
  • Zhang, Zichao
  • Moreland, Alex
  • Mahan, Michael J.
  • Heithoff, Douglas M.
  • Limwongyut, Jakkarin
  • Nie, Chenyao

Abstract

Compositions and methods of making and using thereof are provided with a specific antimicrobial activity and efficacy toward Gram-positive and Gram-negative bacteria and low levels of toxicity toward mammalian cells. The compositions include water-soluble molecules characterized by a hydrophobic interior fragment and side groups containing cationic groups. A class of these molecules is provided with variations in the length of the internal conjugated segment and in other molecular features, which impact the efficacy and toxicity. The substituents on the cationic functional group, the structural variations on the solubilizing group, and the length of the conjugated segment are important features affecting the antimicrobial property and the non-toxicity to mammalian cells of the composition.

IPC Classes  ?

  • C07D 471/08 - Bridged systems
  • A61P 31/04 - Antibacterial agents
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07C 217/62 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
  • C07C 279/08 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
  • C07C 309/24 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings

19.

VIRUS BIORESISTORS

      
Application Number 17043191
Status Pending
Filing Date 2019-03-29
First Publication Date 2021-01-21
Owner
  • The Regents of the University of California (USA)
  • Phagetech, Inc. (USA)
Inventor
  • Penner, Reginald M.
  • Ogata, Alana F.
  • Bhasin, Apurva
  • Weiss, Gregory A.
  • Tam, Phillip
  • Briggs, Jeffrey Scott
  • Yap-True, Marie
  • Attar, Aisha
  • Patterson, Shae Victoria

Abstract

Provided herein are, inter alia, biosensors and electrochemical cells comprising electronically conductive polymers and viral particles; diagnostic kits; and methods of detecting compounds in samples.

IPC Classes  ?

  • G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
  • G01N 27/327 - Biochemical electrodes
  • G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance

20.

ANTI-CANCER COMPOUNDS

      
Application Number 16790287
Status Pending
Filing Date 2020-02-13
First Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Peto, Csaba J.
  • Jablons, David
  • Lemjabbar-Alaoui, Hassan

Abstract

This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.

IPC Classes  ?

  • C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
  • A61P 35/00 - Antineoplastic agents
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

21.

PEER-TO-PEER TRAINING OF A MACHINE LEARNING MODEL

      
Application Number 16926534
Status Pending
Filing Date 2020-07-10
First Publication Date 2021-01-14
Owner The Regents of the University of California (USA)
Inventor
  • Lalitha, Anusha
  • Javidi, Tara
  • Koushanfar, Farinaz
  • Kilinc, Osman Cihan

Abstract

A method may include training, based on a first training data available at a first node in a network, a first local machine learning model. A first local belief of a parameter set of a global machine learning model may be updated based on the training of the first local machine learning model. A second local belief of the parameter set of the global machine learning model may be received from a second node in the network. The second local belief may have been updated based on the second node training a second local machine learning model. The second local machine learning model may be trained based on a second training data available at the second node. The first local belief may be updated based on the second local belief of the second node. Related systems and articles of manufacture, including computer program products, are also provided.

IPC Classes  ?

22.

TRUNK SUPPORTING EXOSKELETON AND METHOD OF USE

      
Application Number 17038328
Status Pending
Filing Date 2020-09-30
First Publication Date 2021-01-14
Owner The Regents of the University of California (USA)
Inventor
  • Kazerooni, Homayoon
  • Hacker, Erich
  • Chen, Lee-Huang

Abstract

An exoskeleton includes two torque generators, two thigh links, and a supporting trunk rotatably coupled to the thigh links. When a wearer bends forward in the sagittal plane such that the supporting trunk extends beyond a predetermined angle A with respect to vertical, at least one of the torque generators imposes a resisting torque between the supporting trunk and a corresponding thigh link, thus imposing a force onto a wearer's trunk and thighs to aid in supporting the wearer in a bent position. The exoskeleton may include an active or passive means for actuating the generators. When the supporting trunk does not extend beyond the predetermined angle A, the torque generators do not impose resisting torques between the supporting trunk and the thigh links during the entire range of motion of the thigh links, thus enabling a wearer to walk, run and sit without constraint while in an upright position.

IPC Classes  ?

23.

Compounds and Compositions for the Treatment of Cancer

      
Application Number 16305377
Status Pending
Filing Date 2017-06-28
First Publication Date 2021-01-14
Owner
  • The Regents of the University of California (USA)
  • Rescue Therapeutics, Inc. (USA)
Inventor
  • Peto, Csaba
  • Tolani, Bhairavi
  • Woodard, Gavitt
  • Tsang, Tsze
  • Mann, Michael
  • Jablons, David M.
  • He, Biao

Abstract

The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.

IPC Classes  ?

  • C07D 231/06 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

24.

CHELATING MOLECULES

      
Application Number 16336665
Status Pending
Filing Date 2017-08-28
First Publication Date 2021-01-14
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • FRED HUTCHINSON CANCER RESEARCH CENTER (USA)
Inventor
  • Abergel, Rebecca J.
  • Rees, Julian
  • Strong, Roland K.
  • Captain, Llya

Abstract

Provided herein are a variety of metal chelators as well as methods of use thereof.

IPC Classes  ?

  • C07C 235/60 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • A61K 51/04 - Organic compounds
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
  • A61K 38/07 - Tetrapeptides
  • C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

25.

MAGNETIC MEMORY STRUCTURES USING ELECTRIC-FIELD CONTROLLED INTERLAYER EXCHANGE COUPLING (IEC) FOR MAGNETIZATION SWITCHING

      
Application Number 16510343
Status Pending
Filing Date 2019-07-12
First Publication Date 2021-01-14
Owner The Regents of the University of California (USA)
Inventor
  • Salahuddin, Sayeef
  • Sayed, Shehrin

Abstract

A magnetic memory structure employs electric-field controlled interlayer exchange coupling between a free magnetic layer and a fixed magnetic layer to switch a magnetization direction. The magnetic layers are separated by a spacer layer disposed between two oxide layers. The spacer layer exhibits a large IEC while the oxide layers provide tunnel barriers, forming a quantum-well between the magnetic layers with discrete energy states above the equilibrium Fermi level. When an electric field is applied across the structure, the tunnel barriers become transparent at discrete energy states via a resonant tunneling phenomenon. The wave functions of the two magnets then can interact and interfere to provide a sizable IEC. IEC can control the magnetization direction of the free magnetic layer relative to the magnetization direction of the fixed magnetic layer depending on the sign of the IEC, induced by a magnitude of the applied electric field above a threshold value.

IPC Classes  ?

  • H01F 10/32 - Spin-exchange-coupled multilayers, e.g. nanostructured superlattices
  • H01L 43/10 - Selection of materials
  • H01L 43/02 - Devices using galvano-magnetic or similar magnetic effects; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details
  • G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect

26.

COMPOUNDS AND METHODS FOR TREATING FIBROSIS OR CANCER

      
Application Number 16305172
Status Pending
Filing Date 2017-06-02
First Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Chapman, Harold A.
  • Wei, Ying
  • Backes, Bradley J.

Abstract

Provided herein, inter alia, are methods and compounds for treating a pulmonary disease, fibrosis, or cancer.

IPC Classes  ?

  • C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
  • C07D 321/10 - Seven-membered rings condensed with carbocyclic rings or ring systems
  • C07D 273/01 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups having one nitrogen atom

27.

Photodiode

      
Application Number 16504724
Status Pending
Filing Date 2019-07-08
First Publication Date 2021-01-14
Owner
  • University College Cardiff Consultants Limited (United Kingdom)
  • The Regents of The University of California (USA)
  • University of Sheffield (United Kingdom)
Inventor
  • Liang, Baolai
  • Xie, Shiyu
  • Huffaker, Diana Lynne
  • David, John Paul Raj
  • Tan, Chee Hing

Abstract

In an example, an avalanche photodiode comprises a substrate and a structure comprising a first layer and a second layer, the first and second layers over and parallel to the substrate, wherein the first layer is between the substrate and the second layer. The first layer is an Aluminium Arsenide Antimonide multiplication layer, and wherein the cross-sectional area parallel to the substrate of the first layer is smaller than that of the second layer, thereby forming a recess in a sidewall of the structure.

IPC Classes  ?

  • H01L 31/107 - Devices sensitive to infra-red, visible or ultra-violet radiation characterised by only one potential barrier or surface barrier the potential barrier working in avalanche mode, e.g. avalanche photodiode
  • H01L 31/0216 - Coatings
  • H01L 31/0304 - Inorganic materials including, apart from doping materials or other impurities, only AIIIBV compounds
  • H01L 31/0352 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions
  • H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof

28.

USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION

      
Application Number 16863892
Status Pending
Filing Date 2020-04-30
First Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Haudenschild, Dominik
  • Di Cesare, Paul
  • Yik, Jasper
  • Christiansen, Blaine

Abstract

The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

IPC Classes  ?

  • A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A01N 1/02 - Preservation of living parts
  • A61K 9/00 - Medicinal preparations characterised by special physical form

29.

HOUSING FOR STORAGE AND MANIPULATION OF A SURGICAL GUIDE WIRE

      
Application Number 16911855
Status Pending
Filing Date 2020-06-25
First Publication Date 2021-01-14
Owner The Regents of the University of California (USA)
Inventor Wehbi, Elias

Abstract

A housing has a spiral passageway which contains a catheter which may be manually extracted from the housing by means of a wheel having a polygonal or otherwise textured circumferential surface and mounted on a shaft which extends through a non-circular bearing defined in an outer portion of the housing. An inner portion of the wheel extends into the spiral passageway adjacent the wire catheter and an outer portion of the wheel outwardly from the housing whereby the upper surface of the knob can be manipulated by a member of the surgical team in one direction and the wire catheter below the knob will be advanced in the opposite direction. The non-circular bearing has a generally circular outer portion in which the textured surface of the knob is only intermittently in contact with the catheter whereby the wire catheter may be advanced, and a generally linear inner portion sloping inwardly towards the catheter. When the knob's shaft is held loosely in the outer portion of the bearing, the wire catheter is free to travel. However when the knob's shaft is moved into the sloping portion of the bearing, the operator can push the knob in one direction to force the knob against the wire catheter and lock the catheter into intimate contact with the lower surface of the passageway, and in the opposite direction to retract the knob slightly away from the catheter thereby permitting limited movement of the catheter relative to the housing.

IPC Classes  ?

30.

FULLY AUTOMATED FOUR-CHAMBER SEGMENTATION OF ECHOCARDIOGRAMS

      
Application Number 16926517
Status Pending
Filing Date 2020-07-10
First Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Arafati, Arghavan
  • Jafarkhani, Hamid
  • Kheradvar, Arash

Abstract

Devices, systems and methods related to techniques for performing four-chamber segmentation of echocardiograms are disclosed. In one example aspect, a method for generating segmented image data based on an input echocardiogram includes receiving an input echocardiogram that includes information associated with four chambers of a heart, performing segmentation on the information associated with the four chambers using an adversarial model that comprises a first artificial neural network with multiple layers, and combining data from selected layers of the first artificial neural network to generate an output image that includes the segmented four chambers of the heart.

IPC Classes  ?

  • G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
  • G06N 3/08 - Learning methods

31.

OPTICAL CAVITY PCR

      
Application Number 16938197
Status Pending
Filing Date 2020-07-24
First Publication Date 2021-01-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lee, Luke P.
  • Son, Jun Ho

Abstract

An LED-driven optical cavity PCR system and method is disclosed for fast, accurate and reliable PCR based diagnostics. An optical cavity comprising two thin light absorbing metal (AU) films is used for uniform light absorption and subsequent photo thermal light-to-heat conversion is employed for PCR thermal cycling.

IPC Classes  ?

  • B01L 7/00 - Heating or cooling apparatus; Heat insulating devices
  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • C12Q 1/686 - Polymerase chain reaction [PCR]

32.

ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES

      
Application Number 16938577
Status Pending
Filing Date 2020-07-24
First Publication Date 2021-01-14
Owner The Regents of the University of California (USA)
Inventor Voskuhl, Rhonda R.

Abstract

The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

IPC Classes  ?

  • A61K 31/05 - Phenols
  • C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
  • C07D 487/04 - Ortho-condensed systems
  • C07D 307/82 - Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
  • A61K 31/225 - Polycarboxylic acids
  • A61K 38/21 - Interferons
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • C07C 39/42 - Halogenated derivatives containing six-membered aromatic rings and other rings
  • A61K 38/13 - Cyclosporins

33.

METHOD OF FABRICATING NON-POLAR AND SEMI-POLAR DEVICES USING EPITAXIAL LATERAL OVERGROWTH

      
Application Number 16978493
Status Pending
Filing Date 2019-04-01
First Publication Date 2021-01-14
Owner The Regents of the University of California (USA)
Inventor
  • Kamikawa, Takeshi
  • Gandrothula, Srinivas
  • Li, Hongjian

Abstract

A method of fabricating a semiconductor device, comprising: forming a growth restrict mask on or above a III-nitride substrate, and growing one or more island-like III-nitride semiconductor layers on the III-nitride substrate using the growth restrict mask The III-nitride substrate has an in-plane distribution of off-angle orientations with more than 0.1 degree; and the off-angle orientations of an m-plane oriented crystalline surface plane range from about +28 degrees to about −47 degrees towards a c-plane. The island-like III-nitride semiconductor layers have at least one long side and short side, wherein the long side is perpendicular to an a-axis of the island-like III-nitride semiconductor layers. The island-like III-nitride semiconductor layers do not coalesce with neighboring island-like III-nitride semiconductor layers.

IPC Classes  ?

  • H01L 33/00 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof
  • H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
  • H01L 33/18 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region
  • H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
  • H01L 29/04 - Semiconductor bodies characterised by their crystalline structure, e.g. polycrystalline, cubic or particular orientation of crystalline planes
  • H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
  • H01S 5/343 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well lasers [SQW-lasers], multiple quantum well lasers [MQW-lasers] or graded index separate confinement heterostructure lasers [GRINSCH-lasers] in AIIIBV compounds, e.g. AlGaAs-laser
  • H01S 5/22 - Structure or shape of the semiconductor body to guide the optical wave having a ridge or a stripe structure
  • H01S 5/042 - Electrical excitation
  • C30B 25/04 - Pattern deposit, e.g. by using masks
  • C30B 29/40 - AIIIBV compounds

34.

SYNTHETIC PLATELETS

      
Application Number 17030519
Status Pending
Filing Date 2020-09-24
First Publication Date 2021-01-14
Owner
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mitragotri, Samir
  • Sarode, Apoorva
  • Gao, Yongsheng

Abstract

Provided herein are particles comprising a polymer substrate comprising one or more hyaluronic acid chains; and two or more peptide moieties bound directly to each hyaluronic acid chain. In some embodiments, the two or more peptide moieties comprising collagen-binding peptide (CBP) and von Willebrand binding peptide (VBP). The particles can be utilized in, e.g., methods of hemostatic treatment.

IPC Classes  ?

  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61P 7/02 - Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
  • A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
  • A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

35.

SYNTHETIC BIOLOGY TOOLS

      
Application Number 16789993
Status Pending
Filing Date 2020-02-13
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Lou, Chunbo
  • Moon, Tae Seok
  • Rhodius, Virgil
  • Stanton, Brynne
  • Tasmir, Alvin
  • Temme, Karsten
  • Voigt, Chris

Abstract

Methods for design of genetic circuits are provided.

IPC Classes  ?

  • G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
  • G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
  • G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
  • G16C 20/60 - In silico combinatorial chemistry
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/70 - Vectors or expression systems specially adapted for E. coli
  • C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

36.

SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH

      
Application Number 16843783
Status Pending
Filing Date 2020-04-08
First Publication Date 2021-01-07
Owner
  • LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Denardo, Sally J.
  • Denardo, Gerald L.
  • Balhorn, Rodney L.

Abstract

This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.

IPC Classes  ?

  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

37.

PCR-Activated Sorting (PAS)

      
Application Number 16856343
Status Pending
Filing Date 2020-04-23
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Abate, Adam R.
  • Eastburn, Dennis Jay
  • Sciambi, Adam R.
  • Lim, Shaun

Abstract

The methods described herein, referred to as PCR-Activated Sorting (PAS), allow nucleic acids contained in biological systems to be sorted based on their sequence as detected with nucleic acid amplification techniques, e.g., PCR. The nucleic acids can be free floating or contained within living or nonliving structures, including particles, viruses, and cells. The nucleic acids can include, e.g., DNA or RNA. Systems and devices for use in practicing methods of the invention are also provided.

IPC Classes  ?

  • C12Q 1/686 - Polymerase chain reaction [PCR]
  • C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

38.

STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION

      
Application Number 16883515
Status Pending
Filing Date 2020-05-26
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Eisenberg, David S.
  • Sangwan, Smriti
  • Jiang, Lin

Abstract

This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.

IPC Classes  ?

  • C07K 7/02 - Linear peptides containing at least one abnormal peptide link
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
  • A61P 25/16 - Anti-Parkinson drugs

39.

ADAPTIVE ANY-FUEL CAMLESS RECIPROCATING ENGINE

      
Application Number 16929544
Status Pending
Filing Date 2020-07-15
First Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Spearrin, Raymond Mitchell
  • Tsao, Tsu-Chin
  • Sinsheimer, Peter

Abstract

An adaptive, any-fuel reciprocating engine using sensor feedback integration of high-speed optical sensors with real-time control loops to adaptively manage the electronic actuation schemes over a range of engine loads and fuels. The engine uses one or more optical sensors to collect specific types of gas property data via a spectroscopic technique to adaptively control various components within the engine.

IPC Classes  ?

  • F02D 41/14 - Introducing closed-loop corrections
  • F01L 9/04 - Valve-gear or valve arrangements actuated non-mechanically by electric means
  • F02D 13/02 - Controlling the engine output power by varying inlet or exhaust valve operating characteristics, e.g. timing during engine operation
  • F02D 15/00 - Varying compression ratio
  • F02D 35/02 - Non-electrical control of engines, dependent on conditions exterior or interior to engines, not otherwise provided for on interior conditions
  • F02P 5/145 - Advancing or retarding electric ignition spark; Control therefor automatically, as a function of the working conditions of the engine or vehicle or of the atmospheric conditions using electrical means

40.

METHODS, SYSTEMS, AND COMPOSITIONS FOR DELIVERY OF NANOBUBBLES IN WATER TREATMENT SYSTEMS

      
Application Number 16931201
Status Pending
Filing Date 2020-07-16
First Publication Date 2021-01-07
Owner The Regents of The University of California (USA)
Inventor
  • Earthman, James C.
  • Misra, Mahendra K.
  • Slingsby, Stephen D.

Abstract

Methods, systems, and devices for water treatment or for preventing fouling of components of water treatment systems can include the upstream introduction of nanobubbles in-line and/or in close proximity to a reverse osmosis membrane in the water treatment system. The nanobubbles can bind to and cluster (flocculate) nanoparticles (and possible larger solid particles) so that they can be removed and not foul water purification components such as reverse osmosis membranes. The nanobubbles can also interact with and change some characteristics of nanoparticles and thereby reduce fouling of some system components, such as reverse osmosis membranes, or other components. The systems, methods, and devices disclosed herein can help produce potable water safe for human consumption in a more cost-effective manner, e.g., by reducing maintenance costs and in some cases manufacturing costs.

IPC Classes  ?

  • B01D 61/04 - Feed pretreatment
  • B01D 61/08 - Apparatus therefor
  • B01D 61/02 - Reverse osmosis; Hyperfiltration
  • B01D 65/08 - Prevention of membrane fouling or of concentration polarisation
  • C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
  • C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
  • C02F 1/00 - Treatment of water, waste water, or sewage
  • C02F 1/24 - Treatment of water, waste water, or sewage by flotation

41.

COMPOSITIONS AND METHODS INVOLVING ENGINEERED P27

      
Application Number 16977441
Status Pending
Filing Date 2019-04-10
First Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Rubin, Seth
  • Guiley, Keelan

Abstract

The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof. Such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.

IPC Classes  ?

  • C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
  • C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

42.

DRUG DELIVERY FORMULATIONS

      
Application Number 16982891
Status Pending
Filing Date 2019-03-26
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Sailor, Michael J.
  • Hollett, Geoffrey Ian
  • Ingallinera, Thomas

Abstract

The disclosure provides drug delivery formulations that comprise a porous silicon material and a meltable compound, such as a progestin drug, or a meltable composition. The formulations provide for the controlled release of the progestin drug, or other therapeutic agent, over long time periods. In some embodiments, the meltable composition further comprises a melting point suppression agent, where the melting point suppression agent enables the loading of thermally unstable therapeutic agents into the porous silicon material by melt casting that would not otherwise be possible absent the melting point suppression agent. The disclosure additionally provides methods of making and using the drug delivery formulations.

IPC Classes  ?

  • A61K 9/16 - Agglomerates; Granulates; Microbeadlets
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
  • A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

43.

Host cells and methods for producing toluene biochemically

      
Application Number 16286411
Status Pending
Filing Date 2019-02-26
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Beller, Harry R.
  • Rodrigues, Andria V.
  • Zargar, Kamrun

Abstract

The present invention provides for a genetically modified host cell comprising a first polypeptide comprising a sequence having at least 70% amino acid sequence identity with a phenylacetate decarboxylase, and having an enzymatic activity to decarboxylate a phenylacetic acid into a toluene and a carbon dioxide, and a second polypeptide comprising a sequence having at least 70% amino acid sequence identity with a phenylacetate decarboxylase activating enzyme, and having an enzymatic activity to cleave a S-adenosylmethionine (SAM) to form a methionine and a 5′-deoxyadenosyl radical.

IPC Classes  ?

  • C12P 5/00 - Preparation of hydrocarbons
  • C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
  • C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N 9/14 - Hydrolases (3.)

44.

Split Trans-Complementing Gene-Drive System for Suppressing Aedes Aegypti Mosquitos

      
Application Number 16325110
Status Pending
Filing Date 2017-08-17
First Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bier, Ethan
  • Gantz, Valentino
  • James, Anthony A.

Abstract

Provided are systems, constructs, genetically modified organisms, and methods for greatly reducing or eliminating local populations of Aedes aegypti mosquitoes, and associated Dengue fever, yellow fever, Zika virus, and Chikungunya virus. Provided are genetically modified Aedes aegypti having a Cas9-mediated split gene-drive system for masculinizing the mosquito and ensuring that any female carries a sterile mutation. In addition, gRNAs direct Cas9 cleavage of insecticide-resistance loci, rendering female mosquitoes escaping the male converting gene drive sensitive to insecticides.

IPC Classes  ?

  • A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates
  • C12N 9/22 - Ribonucleases

45.

MICROFLUIDIC-ENABLED MULTIWELL CELL CULTURE DEVICES AND SYSTEMS FOR PRECISION CULTURE, CONTROL AND MONITORING OF LIVING CELLS

      
Application Number 16614290
Status Pending
Filing Date 2018-05-15
First Publication Date 2021-01-07
Owner
  • Cairn Biosciences, Inc. (USA)
  • The Regents of the University of California (USA)
Inventor
  • Ludlam, Mary J. C.
  • Blanco, Austin
  • Wartmann, David
  • Mathies, Richard A.

Abstract

Devices, systems, methods, and techniques regarding a microfluidic-enabled multiwell device with closed-loop monitoring and control of various parameters of the microfluidic environment are provided. A microfluidic-enabled multiwell device may have a removable and disposable microfluidics module layer and a reusable sensor module layer. The sensor module layer may be configured to monitor and control parameters of the environment inside the microfluidics module layer, store data regarding the parameters, and wirelessly transmit the data. The device may be configured to individually address flow of fluid to any one of a plurality of wells, using one or more pneumatic micropumps. The device may be configured to automatically execute one or more live cell cultures, assays, and/or protocols. The device may be configured to be received in a docking station and/or portable manifold adapter, and to be fluidly, pneumatically, and/or electronically coupled to the station, adapter, or other laboratory equipment.

IPC Classes  ?

  • C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
  • C12M 1/32 - Inoculator or sampler multiple field or continuous type
  • C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
  • C12M 1/00 - Apparatus for enzymology or microbiology
  • C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

46.

STEM CELL-DERIVED EXOSOMES FOR THE TREATMENT OF CORNEAL SCARRING

      
Application Number 16977015
Status Pending
Filing Date 2019-03-04
First Publication Date 2021-01-07
Owner
  • University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
  • The Regents of the University of California (USA)
Inventor
  • Deng, Sophie Xiaohui
  • Funderburgh, James L.

Abstract

Corneal stromal scars are the leading cause of corneal blindness. The present invention relates to methods and compositions useful in therapies for this pathological condition. The invention provides corneal stromal stem cells and certain other stem cells and as well as exosome polynucleotides produced by such cells, and methods for making and using these cells and compositions. The invention is based upon the discovery that exosomes and their associate active components obtained from these cells comprise agents having the same capacity as corneal stromal stem cells to reduce scarring and prevent scar formation in patients having corneal damage.

IPC Classes  ?

  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 9/00 - Medicinal preparations characterised by special physical form

47.

AUTOMATED CARDIAC FUNCTION ASSESSMENT BY ECHOCARDIOGRAPHY

      
Application Number 16977418
Status Pending
Filing Date 2019-03-14
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Deo, Rahul C.
  • Zhang, Jeffrey

Abstract

A computer vision pipeline is provided for fully automated interpretation of cardiac function, using a combination of machine learning strategies to enable building a scalable analysis pipeline for echocardiogram interpretation. Videos from patients with heart failure can be analyzed and processed as follows: 1) preprocessing of echo studies; 2) convolutional neural networks (CNN) processing for view identification; 3) segmentation of chambers and delineation of cardiac boundaries using CNNs; 4); particle tracking to compute longitudinal strain; and 5) targeted disease detection.

IPC Classes  ?

  • A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
  • A61B 8/06 - Measuring blood flow
  • A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
  • G06T 7/00 - Image analysis
  • G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G06N 3/08 - Learning methods

48.

BIOREACTIVE COMPOSITIONS AND METHODS OF USE THEREOF

      
Application Number 16977439
Status Pending
Filing Date 2019-03-08
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Wang, Lei
  • Wang, Nanxi

Abstract

Provided herein are, inter alia, non-toxic, bioreactive unnatural amino acids and methods of using same.

IPC Classes  ?

  • C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
  • C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
  • C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

49.

DOCKING SYSTEM TO STABILIZE EYEBALL DURING INTRAOCULAR SURGERY

      
Application Number 17021925
Status Pending
Filing Date 2020-09-15
First Publication Date 2021-01-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Gerber, Matthew
  • Lee, Yu-Hsiu
  • Tsao, Tsu-Chin
  • Rosen, Jacob
  • Hubschman, Jean-Pierre

Abstract

A docking system for intraocular surgery that is configured to simultaneously: (1) physically stabilize a position and an orientation of an eye during intraocular surgical procedures; (2) preserve an unobstructed path for optical instruments; (3) provide access to the eye that allows for tool movement; (4) maintain eyeball hydration and improve the scan quality of an imaging system, such as an OCT system or a surgical microscope and may maintain or control an intraocular pressure of the eye to a stable, desired level during surgical procedures.

IPC Classes  ?

  • A61B 90/50 - Supports for surgical instruments, e.g. articulated arms
  • A61F 9/007 - Methods or devices for eye surgery
  • A61B 90/20 - Surgical microscopes characterised by non-optical aspects

50.

Novel Lanthanide Doped Cesium Barium Halide Scintillators

      
Application Number 17024590
Status Pending
Filing Date 2020-09-17
First Publication Date 2021-01-07
Owner The Regents of the University of California (USA)
Inventor
  • Borade, Ramesh B.
  • Bizarri, Gregory A.
  • Bourret-Courchesne, Edith D.
  • Derenzo, Stephen E.
  • Hanrahan, Stephen M.
  • Yan, Zewu
  • Chaudry, Anurag
  • Canning, Andrew

Abstract

The present invention provides for a composition comprising an inorganic scintillator comprising an optionally lanthanide-doped cesium barium halide, useful for detecting nuclear material.

IPC Classes  ?

  • G01T 1/202 - Measuring radiation intensity with scintillation detectors the detector being a crystal
  • C09K 11/77 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals
  • G21K 4/00 - Conversion screens for the conversion of the spatial distribution of particles or ionising radiation into visible images, e.g. fluoroscopic screens

51.

Chemically modified surfaces with self-assembled aromatic functionalities

      
Application Number 15454878
Grant Number 10883000
Status In Force
Filing Date 2017-03-09
First Publication Date 2021-01-05
Grant Date 2021-01-05
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Yang, Jenny Y.
  • Lydon, Brian R.

Abstract

Materials and methods of modifying an electrode surface are described herein. Self-assembled monolayers (SAM) of polyaromatic molecules covalently attached and form a graphitic-like surface on the electrode surface. After covalent attachment of the polyaromatic monolayer to the surface, polyaromatic-functionalized molecular species is physisorbed onto the surface using the π-interactions. This concept can be applied to generate high performance electrode materials modified with molecular species. The electrode materials can be applied in photoelectrochemical cells, electrochemical cells, sensors, and electrochromic materials. This approach overcomes the major synthetic challenges to modifying surfaces with molecular species, in addition to protecting the surfaces from corrosion.

IPC Classes  ?

  • C09D 5/08 - Anti-corrosive paints
  • C07F 17/02 - Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
  • G01N 27/30 - Electrodes, e.g. test electrodes; Half-cells
  • C23F 13/00 - Inhibiting corrosion of metals by anodic or cathodic protection

52.

METHOD AND APPARATUS FOR EFFICIENT COMMUNICATION PACKET GENERATION IN INTERNET OF THINGS (IOT)

      
Application Number 16914778
Status Pending
Filing Date 2020-06-29
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Guimaraes, Vinicius Galvao
  • Obraczka, Katia
  • Bauchspiess, Adolfo
  • De Moraes, Renato Mariz

Abstract

Techniques for efficient communication packet generation in internet of things (IOT) include presenting an application programming interface to each of a plurality of protocols in a plurality of different layers of a network communications protocol stack. A single packet buffer is configured in memory to hold headers for all of the plurality of protocols for a packet directed to a first destination node. Pointers are also stored in memory to tables maintained by the plurality of protocols. In response to receiving input at the application programming interface from a first protocol, at least one bit is updated in the single packet buffer based on the input and on data in a table maintained by a different second protocol of the plurality of protocols.

IPC Classes  ?

  • H04L 29/06 - Communication control; Communication processing characterised by a protocol
  • H04L 12/861 - Packet buffering or queuing arrangements; Queue scheduling
  • H04W 28/02 - Traffic management, e.g. flow control or congestion control

53.

VERSATILE, HIGH-YIELD PROTEIN PRODUCTION EX VIVO

      
Application Number 16914997
Status Pending
Filing Date 2020-06-29
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Tan, Cheemeng
  • Llano, Luis Eduardo Contreras
  • Meyer, Conary
  • Villarreal, Fernando

Abstract

A cell lysate or cell-free protein synthesis system comprising recombinant translational proteins and uses thereof are provided.

IPC Classes  ?

  • C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C12N 15/67 - General methods for enhancing the expression

54.

THRESHOLD-STIMULATED PLASMA KALLIKREIN ACTIVITY AS A BIOMARKER FOR DIAGNOSIS OF BRADYKININ-MEDIATED ANGIOEDEMA

      
Application Number 16971664
Status Pending
Filing Date 2019-02-22
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Zuraw, Bruce
  • Lara-Marquez, Maria Luz

Abstract

Provided is a diagnostic test for the positive identification of patients with bradykinin-mediated angioedema. The test is valuable for distinguishing bradykinin-mediated angioedema from non-bradykinin-mediated angioedema. The test allows clinicians to clearly separate patients with bradykinin-mediated from histamine-mediated angioedema. Results can be obtained in under an hour, allowing for the proper treatment of angioedema based on the underlying etiology.

IPC Classes  ?

  • C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
  • C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms

55.

Electrochemical Removal of Arsenic Using An Air Diffusion Cathode

      
Application Number 16976705
Status Pending
Filing Date 2019-03-04
First Publication Date 2020-12-31
Owner
  • The Regents of the University of California (USA)
  • Universiteit Utrecht Holding B.V. (Netherlands)
Inventor
  • Gadgil, Ashok
  • Bandaru, Siva Rama Satyam
  • Van Genuchten, Case

Abstract

The present invention provides methods for removing arsenic from an aqueous solution containing dissolved arsenic using a continuous-flow air-cathode iron electrocoagulation device and current densities of from at least 30 mA·cm−2 to about 250 mA·cm−2. The present invention also provides continuous-flow air-cathode iron electrocoagulation devices having barriers for reducing electrode fouling and maintaining faradaic efficiency for longer periods of time.

IPC Classes  ?

  • C02F 1/463 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrocoagulation
  • C02F 1/467 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection

56.

MODULAR SYSTEM FOR GENE AND PROTEIN DELIVERY BASED ON AAV

      
Application Number 16976720
Status Pending
Filing Date 2019-02-28
First Publication Date 2020-12-31
Owner
  • University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
  • The Regents of the University of California (USA)
Inventor
  • Byrne, Leah
  • Ozturk, Bilge Esin
  • Day, Timothy

Abstract

In one embodiment, the invention provides an Adeno-Associated Virus (AAV) comprising an exterior surface, which surface comprises one or more peptide tags that form a bond with a binding-partner, wherein the AAV is a live virus. In another embodiment, the invention provides a conjugate comprising at least one such AAV and at least one polypeptide comprising a first domain which is the binding-partner for the tag and a second domain, which is a bioactive polypeptide. In another embodiment, the invention provides a conjugate comprising at least one such AAV (first AAV) and at least one second AAV, which second AAV comprises a second exterior surface, which second exterior surface comprises at least one binding-partner for the tag or for a third linker molecule, wherein the at least one first AAV and the at least one second AAV are bound.

IPC Classes  ?

  • C12N 15/86 - Viral vectors
  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

57.

REDUCTION OF MILK GLYCANS AND THEIR DEGRADATION PRODUCTS IN THE NEONATE GUT

      
Application Number 16996732
Status Pending
Filing Date 2020-08-18
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Mills, David A.
  • Frese, Steven A.

Abstract

Methods of reducing milk glycans, and thus enteric pathogens that use such glycans as carbon sources, in the gut of nursing mammals.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A01N 63/10 - Animals; Substances produced thereby or obtained therefrom
  • C12R 1/225 - Lactobacillus

58.

TUNABLE LINEAR FLUOROPOLYMERS

      
Application Number 16764680
Status Pending
Filing Date 2018-11-16
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Sletten, Ellen M.
  • Jaye, Joseph A.

Abstract

The present disclosure provides tunable fluoropolymers and methods for making them.

IPC Classes  ?

  • C08F 214/18 - Monomers containing fluorine
  • C08F 138/00 - Homopolymers of compounds having one or more carbon-to-carbon triple bonds
  • C08F 118/12 - Esters of monocarboxylic acids with unsaturated alcohols containing three or more carbon atoms
  • C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
  • C08F 8/26 - Removing halogen atoms or halogen-containing groups from the molecule

59.

ADDITIVE-FREE MANUFACTURING OF GEOMETRICALLY COMPLEX COMPONENTS FOR ELECTRICAL ENERGY STORAGE SYSTEMS

      
Application Number 16859857
Status Pending
Filing Date 2020-04-27
First Publication Date 2020-12-31
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
Inventor
  • Schoenung, Julie M.
  • Acord, Katherine A.
  • Zheng, Baolong
  • Bertoli, Umberto Scipioni
  • Shapiro, Andrew A.
  • Chen, Qian Nataly
  • West, William C.

Abstract

In some embodiments, high-energy additive manufacturing (HE-AM) (e.g., directed energy deposition, powder injection, powder bed fusion, electron beam melting, solid-state, and ultrasonic) is used to overcome constraints of comparative EES fabrication techniques to produce chemical additive-free electrodes with complex, highly versatile designs for next generation EES. An exemplary rapid fabrication technique provides an approach for improving electrochemical performance while increasing efficiency and sustainability, reducing time to market, and lowering production costs. With this exemplary technique, which utilizes computer models for location specific layer-by-layer fabrication of three-dimensional parts (e.g., versatile design), a high degree of control over processing conditions may be achieved to enhance both the design and performance of EES systems.

IPC Classes  ?

  • H01M 4/04 - Processes of manufacture in general
  • H01M 10/058 - Construction or manufacture
  • H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
  • H01M 10/04 - Construction or manufacture in general

60.

FUSION PROTEINS AND METHODS FOR SITE-DIRECTED GENOME EDITING

      
Application Number 16877020
Status Pending
Filing Date 2020-05-18
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Zheng, Yuxuan
  • Lorenzo, Claire
  • Beal, Peter
  • Fisher, Andrew
  • Monteleone, Leanna

Abstract

In some aspects, the present invention provides methods and compositions for modifying target sites within nucleic acid molecules. In some embodiments, the methods comprise using adenosine deaminases that act on RNA (ADARs), and variants thereof, to modify target sites within DNA-RNA hybrid molecules. In other aspects, ADAR2 variant polypeptides as well as fusion proteins comprising an ADAR catalytic domain and a hybrid nucleic acid binding domain are provided, as are methods for use thereof. Methods for preventing and treating genetic disorders are also provided herein.

IPC Classes  ?

  • C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
  • C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
  • C12N 15/62 - DNA sequences coding for fusion proteins

61.

PI3KGAMMA INHIBITORS

      
Application Number 16911894
Status Pending
Filing Date 2020-06-25
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Varner, Judith
  • Amaro, Rommie
  • Kaneda, Megan
  • Malmstrom, Robert
  • Feher, Victoria

Abstract

The present disclosure relates to PI3Kγ inhibitors and methods of their use.

IPC Classes  ?

  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
  • A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
  • A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4196 - 1,2,4-Triazoles
  • A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

62.

SYSTEMS AND METHODS FOR PRODUCING CARBON NANOSTRUCTURES AND ULTRATHIN ALIGNED CARBON WIRES WITH MULTILAYER TURBOSTRATIC GRAPHENE STRUCTURE

      
Application Number 16915339
Status Pending
Filing Date 2020-06-29
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Madou, Marc
  • Deng, Jufeng
  • Hwu, Alexander
  • Yan, Xingxu

Abstract

Systems and methods are provided for fabricating carbon nanostructures by low voltage near-field electromechanical spinning (LV-NFEMS). Processes described herein can produce ˜2-5 nm carbon nanowires with ultrahigh electrical conductivity using top-down and controlled reductive techniques from a polymer. Configurations are also provided to allow for deposition control and fiber elongation/alignment. One embodiment uses a low voltage near-field electromechanical spinning process to produce a polymer fiber from a polymer solution. Another embodiment of the method uses pyrolysis to convert the produced polymer fiber into a ˜2-5 nm carbon nanowire. System configurations provide advancements in polymer droplet control and control of a sustained jet of polymer solution with the use low voltages. Systems and processes described herein can include use of an array of polymer precursor nanofibers suspended onto a silicon substrate and converted to carbon nanowires. In another embodiment, ultra-thin carbon fibers can be integrated onto a carbon electrode scaffold.

IPC Classes  ?

  • D01D 5/00 - Formation of filaments, threads, or the like
  • D01F 9/32 - Apparatus therefor
  • B29C 48/05 - Filamentary, e.g. strands
  • B29C 48/14 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the particular extruding conditions, e.g. in a modified atmosphere or by using vibration

63.

SYSTEMS, CIRCUITS AND COMPUTER PROGRAM PRODUCTS PROVIDING A FRAMEWORK FOR SECURED COLLABORATIVE TRAINING USING HYPER-DIMENSIONAL VECTOR BASED DATA ENCODING/DECODING AND RELATED METHODS

      
Application Number 16915643
Status Pending
Filing Date 2020-06-29
First Publication Date 2020-12-31
Owner The Regents of the University of Californie (USA)
Inventor
  • Imani, Mohsen
  • Kim, Yeseong
  • Rosing, Tajana
  • Koushanfar, Farinaz
  • Riazi, Mohammad Sadegh

Abstract

A computing system can include a plurality of clients located outside a cloud-based computing environment, where each of the clients may be configured to encode respective original data with a respective unique secret key to generate data hypervectors that encode the original data. A collaborative machine learning system can operate in the cloud-based computing environment and can be operatively coupled to the plurality of clients, where the collaborative machine learning system can be configured to operate on the data hypervectors that encode the original data to train a machine learning model operated by the collaborative machine learning system or to generate an inference from the machine learning model.

IPC Classes  ?

64.

METHODS AND COMPOSITIONS RELATING TO EPOXIDE HYDROLASE GENES

      
Application Number 16976285
Status Pending
Filing Date 2019-03-01
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Lynch, Susan V.
  • Levan, Sophia Rose

Abstract

Provided herein are, inter alia, methods and kits for detecting epoxide hydrolase genes. In embodiments, methods and kits for detecting the risk of developing atopy or asthma are included. Also included are methods for preventing or treating atopy or asthma.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 31/47 - Quinolines; Isoquinolines
  • A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
  • A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
  • A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
  • A61K 35/741 - Probiotics
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61K 35/60 - Fish, e.g. seahorses; Fish eggs
  • A61K 35/745 - Bifidobacteria
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
  • G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
  • G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
  • G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

65.

A HEPATOCYTE-MIMICKING ANTIDOTE FOR ALCOHOL INTOXICATION

      
Application Number 16980582
Status Pending
Filing Date 2019-03-29
First Publication Date 2020-12-31
Owner The Regents of the University of California (USA)
Inventor
  • Lu, Yunfeng
  • Ji, Cheng
  • Xu, Duo
  • Han, Hui

Abstract

Alcohol intoxication causes serious diseases, whereas current treatments are mostly supportive and unable to remove alcohol efficiently. Upon alcohol consumption, alcohol is sequentially oxidized to acetaldehyde and acetate by the endogenous alcohol dehydrogenase and aldehyde dehydrogenase, respectively. We disclose a hepatocyte-mimicking antidote for alcohol intoxication through the co-delivery of the nanocapsules of alcohol oxidase (AOx), catalase (CAT), and aldehyde dehydrogenase (ALDH) to the liver, where AOx and CAT catalyze the oxidation of alcohol to acetaldehyde, while ALDH catalyzes the oxidation of acetaldehyde to acetate. Administered to alcohol-intoxicated mice, the antidote rapidly accumulates in the liver and enables a significant reduction of the blood alcohol concentration. Moreover, blood acetaldehyde concentration is maintained at an extremely low level, significantly contributing to liver protection. Such an antidote, which can eliminate alcohol and acetaldehyde simultaneously, holds great promise for the treatment of alcohol intoxication and poisoning.

IPC Classes  ?

  • A61K 38/44 - Oxidoreductases (1)
  • A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/50 - Microcapsules

66.

FLEXIBLE SPINAL CORD STIMULATORS FOR PAIN AND TRAUMA MANAGEMENT THROUGH NEUROMODULATION

      
Application Number 16981204
Status Pending
Filing Date 2019-03-15
First Publication Date 2020-12-31
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Gaonkar, Bilwaj
  • Moran, Steven L.
  • Hanna, Amir
  • Macyszyn, Luke
  • Iyer, Subramanian S.

Abstract

A spinal cord stimulator includes: (1) a flexible substrate; (2) a power source embedded in the flexible substrate; (3) a controller embedded in the flexible substrate and connected to the power source; and (4) an array of electrodes, including an array of stimulation electrodes, disposed over the flexible substrate and connected to the controller, wherein the controller is configured to direct the array of stimulation electrodes to deliver a stimulation pattern to a spinal cord of a patient.

IPC Classes  ?

  • A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
  • A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
  • A61N 1/378 - Electrical supply

67.

Methods of Treating Dog Urinary Tract Infections

      
Application Number 16769962
Status Pending
Filing Date 2018-12-04
First Publication Date 2020-12-24
Owner
  • The Regents of the University of California (USA)
  • Northwestern University (USA)
Inventor
  • Westropp, Joellen L.
  • Schaeffer, Anthony J.
  • Klumpp, David J.

Abstract

Provided are methods for treating acute and recurring urinary tract infections in dogs.

IPC Classes  ?

  • A61K 35/741 - Probiotics
  • A61K 9/00 - Medicinal preparations characterised by special physical form

68.

LOW-POWER, LOW-NOISE MILLIMETER WAVELENGTH FREQUENCY SYNTHESIZER

      
Application Number 16896866
Status Pending
Filing Date 2020-06-09
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Wang, Hao
  • Momeni, Omeed

Abstract

The system includes an intermediate-frequency (IF) synthesizer that generates an IF signal based on a reference signal, and a sub-sampling PLL (SSPLL) that generates a high-frequency output signal based on an input. A switch selects either the reference signal or the IF signal to be the input to the SSPLL. When the reference signal is the input to the SSPLL, the frequency synthesizer operates in a low-noise normal-operating mode, and when the IF signal is the input to the SSPLL, the frequency synthesizer operates in a higher-noise, frequency-acquisition mode. A sub-sampling lock detector (SSLD) determines whether the frequency synthesizer becomes unlocked during the normal-operating mode, and if so, activates the switch to move the system into the frequency-acquisition mode. It also determines whether the frequency synthesizer becomes relocked to the target frequency during the frequency-acquisition mode, and if so, activates the switch to move the system into the normal-operating mode.

IPC Classes  ?

  • H03L 7/08 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop
  • H03L 7/093 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop concerning mainly the frequency- or phase-detection arrangement including the filtering or amplification of its output signal using special filtering or amplification characteristics in the loop

69.

METHODS FOR IDENTIFYING, COMPOUNDS IDENTIFIED AND COMPOSITIONS THEREOF

      
Application Number 16904413
Status Pending
Filing Date 2020-06-17
First Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ray, Anandasankar
  • Kowalewski, Joel

Abstract

Provided herein are screening methods for identifying one or more compounds that impart a smell, taste and/or trigeminal sensation, for example, odorants contributing to an olfactory quality. Further provided are one or more compounds identified using the screening methods described herein, and compositions containing such compounds.

IPC Classes  ?

  • C11B 9/00 - Essential oils; Perfumes
  • A23L 27/00 - Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof

70.

UNUSUALLY POTENT ABA RECEPTOR PAN-ANTAGONISTS

      
Application Number 16906765
Status Pending
Filing Date 2020-06-19
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Cutler, Sean R.
  • Vaidya, Aditya

Abstract

The present invention sets forth new compounds that potently block activation of ABA receptors. In some aspects, these compounds can be used to enhance germination of crop seeds to stand establishment and to increase transpiration and photosynthetic yields when water is not limiting plant growth.

IPC Classes  ?

  • A01N 43/647 - Triazoles; Hydrogenated triazoles
  • C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

71.

RATCHET-BASED ION PUMPING MEMBRANE SYSTEMS

      
Application Number 16907076
Status Pending
Filing Date 2020-06-19
First Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ardo, Shane
  • Segev, Gideon
  • Toma, Francesca
  • Ager, Joel
  • Kautz, Rylan
  • Larson, David

Abstract

Described herein is an ion pump system implementing an electronic ratchet mechanism produced by modulating a spatially varying electric potential distribution that can result in a net ionic current and voltage. The ion pumping membrane system includes an ion-permeable layer integrated with ion-selective membranes. The electric potential distribution within the ion-permeable layer is modulated through external stimuli. When immersed in solution, ions within the ion-permeable layer experience a time varying, spatially asymmetric electric field distribution resulting in ratchet-driven direction pumping, which can be used in applications such as desalination.

IPC Classes  ?

  • H01J 41/12 - Discharge tubes for evacuating by diffusion of ions, e.g. ion pumps, getter ion pumps
  • B01D 61/46 - Apparatus therefor
  • C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis

72.

SUBPIAL DELIVERY SYSTEM AND METHODS OF USE

      
Application Number 16954146
Status Pending
Filing Date 2020-01-10
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor Marsala, Martin

Abstract

Delivery devices, systems, and methods related thereto may be used on patients for spinal delivery of cells, drugs, or vectors. The patient population may include patients with spinal traumatic injury, amyotrophic lateral sclerosis, multiple sclerosis, spinal ischemia, and other spinal neurodegenerative disorder that will require spinal cell, vector, or drug delivery.

IPC Classes  ?

  • A61B 17/34 - Trocars; Puncturing needles
  • A61B 17/02 - Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
  • A61M 5/178 - Syringes
  • A61M 5/142 - Pressure infusion, e.g. using pumps

73.

METHOD FOR DETECTION AND SEPARATION OF ENANTIOMERS USING VESICLE-LIKE NANOSTRUCTURES SELF-ASSEMBLED FROM JANUS NANOPARTICLES

      
Application Number 16975604
Status Pending
Filing Date 2019-02-14
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Chen, Shaowei
  • Lu, Jia-En

Abstract

A method for processing an analyte includes: adding a plurality of amphiphilic nanoparticles to a solvent to form a mixture having a plurality of enantioselective nanoparticle ensembles; adding an analyte to the mixture; obtaining a test circular dichroism spectrum of the mixture with the analyte; and determining an enantiomeric property of the analyte based on a comparison of a baseline circular dichroism spectrum of the analyte mixture to the test circular dichroism spectrum.

IPC Classes  ?

  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N 21/19 - Dichroism

74.

[1,2,4]TRIAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES

      
Application Number 16977643
Status Pending
Filing Date 2019-02-28
First Publication Date 2020-12-24
Owner
  • THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Brunden, Kurt R.
  • Lee, Virginia M.Y.
  • Trojanowski, John Q.
  • Ballatore, Carlo
  • Oukoloff, Killian
  • Smith, Iii, Amos B.

Abstract

The present disclosure provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Rx-R8 are defined herein. Also provided are compositions comprising a compound described herein and a pharmaceutically effective excipient, methods of stabilizing microtubules in a patient comprising administering to the patient a microtubule-stabilizing amount of a compound described herein, methods of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, and methods of treating a neurodegenerative disease in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein. The present disclosure provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Rx-R8 are defined herein. Also provided are compositions comprising a compound described herein and a pharmaceutically effective excipient, methods of stabilizing microtubules in a patient comprising administering to the patient a microtubule-stabilizing amount of a compound described herein, methods of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, and methods of treating a neurodegenerative disease in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

75.

CO-SOLVENT TO PRODUCE REACTIVE INTERMEDIATES FROM BIOMASS

      
Application Number 17008180
Status Pending
Filing Date 2020-08-31
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Cai, Charles M.
  • Wyman, Charles E.
  • Zhang, Taiying
  • Kumar, Rajeev

Abstract

The disclosure provides a system for production of reactive intermediates from lignocellulosic biomass. The reactive intermediates can be used as platform chemicals for biological conversions or can be further catalytically upgraded to be used as “drop in” reagents for fuels. The disclosure provides methods and compositions useful for processing biomass to biofuels and intermediates.

IPC Classes  ?

  • C13K 1/02 - Glucose; Glucose-containing syrups obtained by saccharification of cellulosic materials
  • C07D 307/08 - Preparation of tetrahydrofuran
  • C07D 307/50 - Preparation from natural products
  • C07G 1/00 - Low-molecular-weight derivatives of lignin
  • C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
  • C12P 19/02 - Monosaccharides
  • D21C 3/20 - Pulping cellulose-containing materials with organic solvents
  • D21C 3/22 - Other features of pulping processes
  • C12P 17/04 - Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin

76.

Systems and Methods for Communicating by Modulating Data on Zeros in the Presence of Channel Impairments

      
Application Number 17013525
Status Pending
Filing Date 2020-09-04
First Publication Date 2020-12-24
Owner
  • California Institute of Technology (USA)
  • The Regents of the University of California (USA)
  • Technische Universität Berlin (Germany)
Inventor
  • Walk, Philipp
  • Hassibi, Babak
  • Jung, Peter
  • Jafarkhani, Hamid

Abstract

Communication systems and methods in accordance with various embodiments of the invention utilize modulation on zeros. Carrier frequency offsets (CFO) can result in an unknown rotation of all zeros of a received signal's z-transform. Therefore, a binary MOCZ scheme (BMOCZ) can be utilized in which the modulated binary data is encoded using a cycling register code (e.g. CPC or ACPC), enabling receivers to determine cyclic shifts in the BMOCZ symbol resulting from a CFO. Receivers in accordance with several embodiments of the invention include decoders capable of decoding information bits from received discrete-time baseband signals by: estimating a timing offset for the received signal; determining a plurality of zeros of a z-transform of the received symbol; identifying zeros from the plurality of zeros that encode received bits by correcting fractional rotations resulting from the CFO; and decoding information bits based upon the received bits using a cycling register code.

IPC Classes  ?

77.

NOVEL RNAi MOLECULE DELIVERY PLATFORM BASED ON SINGLE-siRNA AND shRNA NANOCAPSULES

      
Application Number 16799536
Status Pending
Filing Date 2020-02-24
First Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lu, Yunfeng
  • Chen, Irvin S.Y.
  • Yan, Ming
  • Liang, Min
  • Kamata, Masakazu
  • Wen, Jing

Abstract

Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.

IPC Classes  ?

  • A61K 9/51 - Nanocapsules
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

78.

Gas Exchange Composite Membranes and Methods of Use Thereof

      
Application Number 16868836
Status Pending
Filing Date 2020-05-07
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Roy, Shuvo
  • Yeager, Torin
  • Abada, Emily
  • Dharia, Ajay S.

Abstract

Provided herein is a gas exchange composite membrane and methods of making the same. The gas exchange composite membrane may find use in a method of exchanging gas with blood in a subject in need of blood oxygenation support, which method is also disclosed. Also provided herein are systems and kits that find use in performing the methods of exchanging gas with blood.

IPC Classes  ?

  • A61M 1/16 - Dialysis systems; Artificial kidneys; Blood oxygenators with membranes
  • B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
  • B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
  • B01D 69/12 - Composite membranes; Ultra-thin membranes
  • A61M 1/26 - Dialysis systems; Artificial kidneys; Blood oxygenators with membranes which are moving
  • B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only

79.

FUSOGENIC LIPOSOME-COATED POROUS SILICON NANOPARTICLES

      
Application Number 16920979
Status Pending
Filing Date 2020-07-06
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Sailor, Michael J.
  • Kim, Byungji
  • Kang, Jinyoung

Abstract

The disclosure describes a fusogenic liposome-coated porous silicon nanoparticles for high loading efficiency of anionic payloads (small molecules, dyes, nucleic acids), and for non-endocytic delivery of hydrophilic and lipophilic payloads by membrane fusion. The liposome coating can be further modified with targeting peptides or antibodies via covalent binding chemistry between the ligands and functionalized poly(ethylene glycol). The surface moieties can be transferred to the cellular membrane surface by fusogenic uptake. The composition of the disclosure can be applied in the treatment of diseases by delivering entrapped/encapsulated payloads.

IPC Classes  ?

  • A61K 9/127 - Liposomes
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/51 - Nanocapsules
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

80.

TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNAS

      
Application Number 16927351
Status Pending
Filing Date 2020-07-13
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Doudna, Jennifer A.
  • Chen, Janice S.
  • Harrington, Lucas Benjamin
  • Ma, Enbo

Abstract

Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some embodiments, a subject method includes: (a) contacting the sample with: (i) a type V CRISPR/Cas effector protein (e.g., a Cas12 protein such as Cas12a, Cas12b, Cas12c, Cas12d, Cas12e); (ii) a guide RNA (comprising a region that binds to the type V CRISPR/Cas effector protein, and a guide sequence that hybridizes with the target DNA); and (iii) a detector DNA that is single stranded (i.e., a “single stranded detector DNA”) and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage (by the type V CRISPR/Cas effector protein) of the single stranded detector DNA. Also provided are compositions and methods for cleaving single stranded DNAs (e.g., non-target ssDNAs), e.g., inside of a cell.

IPC Classes  ?

  • C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q 1/6823 - Release of bound markers
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof

81.

pH MODULATION DEVICE ARCHITECTURE MEDIATING METAL OXIDE CATALYSIS FOR METABOLITE SENSING

      
Application Number 16968441
Status Pending
Filing Date 2019-02-13
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Strakosas, Xenofon
  • Selberg, John
  • Rolandi, Marco

Abstract

A non-enzymatic sensor includes a substrate; a sensor contact disposed on the substrate; and a pH modifying contact disposed on the substrate proximate the sensor contact. The pH modifying contact includes a material that absorbs hydrogen from and expels hydrogen to a fluid when in use in response to applied voltages resulting in an electrically controllable change of pH of the fluid. The pH modifying contact is positioned relative to the sensor contact such that the electrically controllable change of pH of the fluid results in a change in pH of the fluid proximal to the sensor contact to thereby enhanced detection of a substance of interest at the sensor contact without the use of enzymes.

IPC Classes  ?

82.

CAR-T CELLS AND AUTOIMMUNE DISEASES

      
Application Number 16968794
Status Pending
Filing Date 2019-02-11
First Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bluestone, Jeffrey A.
  • Raffin, Caroline

Abstract

Chimeric antigen receptor (CAR)-expressing Tregs specifically target an antigen present in the joint of RA patients to induce a localized and effective immunosuppressive response.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 14/725 - T-cell receptors
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

83.

DENTAL ADHESIVE HYDROGELS AND USES THEREOF

      
Application Number 16979215
Status Pending
Filing Date 2019-03-11
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor
  • Moshaverinia, Alireza
  • Hasani-Sadrabadi, Mohammad Mahdi
  • Aghaloo, Tara L.
  • Weiss, Paul S.

Abstract

A dental hydrogel composition comprising: (a) polysaccharide; (b) polydopamine conjugated to the polysaccharide, wherein between 5 and 35 percent of polysaccharide sugar moieties are conjugated to polydopamine; (c) RGD peptide coupled to the polysaccharide-poly-dopamine conjugate; and (d) moieties that are crosslinkable upon exposure to light coupled to the polysaccharide; wherein components (a)-(d) are disposed in the composition such that the hydrogel composition: exhibits an adhesive strength of at least 10 kPa upon cross linking of crosslinkable moieties; and exhibits an elasticity between 5 kPa and 100 kPa upon cross linking of crosslinkable moieties.

IPC Classes  ?

84.

THERMAL DEVICES FOR CONTROLLING HEAT TRANSFER

      
Application Number 17009154
Status Pending
Filing Date 2020-09-01
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor Wang, Yun

Abstract

In one embodiment, a thermal device includes a sealed housing that defines an interior space, a liquid-attracting element provided on one side of the interior space, a liquid-repelling element provided on another side of the interior space opposite to the liquid-attracting element, and a liquid provided within the interior space.

IPC Classes  ?

  • F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
  • F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes

85.

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND DETECTION OF TUMORS AND CANCER PROGNOSIS

      
Application Number 17011732
Status Pending
Filing Date 2020-09-03
First Publication Date 2020-12-24
Owner The Regents of the University of California (USA)
Inventor Califano, Joseph

Abstract

Provided herein are probe and primer pairs that are useful for the detection of HPV in samples isolated from patients.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

86.

NETWORK ON INTERCONNECT FABRIC AND INTEGRATED ANTENNA

      
Application Number 17013166
Status Pending
Filing Date 2020-09-04
First Publication Date 2020-12-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Vaisband, Boris
  • Iyer, Subramanian S.
  • Bajwa, Adeel A.
  • Dasgupta, Arpan
  • Alam, Arsalan

Abstract

A system is provided for interconnecting multiple functional dies on a single substrate, including: (1) multiple global links in the substrate; (2) multiple local links in the substrate; and (3) multiple utility dies on the substrate, wherein each of the utility dies is connected to at least one of the global links, the utility dies are configured to communicate with one another through the global links, each of the utility dies is connected to at least one of the local links and is configured to communicate with at least one of the functional dies through the at least one of the local links. In some embodiments, an antenna is integrated into the substrate.

IPC Classes  ?

  • H01Q 1/22 - Supports; Mounting means by structural association with other equipment or articles
  • H01Q 23/00 - Antennas with active circuits or circuit elements integrated within them or attached to them
  • H01Q 9/04 - Resonant antennas

87.

MANIPULATION OF THE RETINOIC ACID SIGNALING PATHWAY

      
Application Number 16763180
Status Pending
Filing Date 2018-11-16
First Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Kramer, Richard H.
  • Telias, Michel
  • Denlinger, Bristol Layne
  • Helft, Zachary John

Abstract

Disclosed herein, inter alia, are compositions and methods for modulating the retinoic acid receptor signaling pathway and treating vision degeneration.

IPC Classes  ?

  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61P 27/02 - Ophthalmic agents
  • C12N 9/22 - Ribonucleases
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/86 - Viral vectors
  • A61K 9/00 - Medicinal preparations characterised by special physical form

88.

PLASMOFLUIDIC MICROLENSES FOR LABEL-FREE OPTICAL SORTING OF BIOPARTICLES

      
Application Number 16900080
Status Pending
Filing Date 2020-06-12
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Yanik, Ahmet Ali
  • Zhu, Xiangchao
  • Cicek, Ahmet
  • Li, Yixiang

Abstract

An optofluidic device includes: a housing having an inlet port coupled to an inlet side and an outlet port coupled to an outlet side; and a microlens disposed within the housing between the inlet side and the outlet side. A fluid having a plurality of particles flows from the inlet side through the microlens to the outlet side. The optofluidic device further includes a light source configured to emit a light beam in a direction opposite flow direction of the fluid, the light beam defining an optical axis that is perpendicular to the microlens.

IPC Classes  ?

89.

METHODS OF SEQUENCING ANTIBODY CHAINS FROM HYBRIDOMAS AND KITS FOR PRACTICING SAME

      
Application Number 16900541
Status Pending
Filing Date 2020-06-12
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Vollmers, Christopher
  • Dubois, Rebecca
  • Meyer, Lena

Abstract

Aspects of the present disclosure include methods of sequencing antibody chains from hybridomas. In some embodiments, the methods comprise contacting hybridoma RNA with a constant region-specific reverse transcription primer, and contacting the hybridoma RNA with a reverse transcriptase with terminal nucleotidyl transferase activity, thereby creating a heavy chain and/or light chain cDNA. Such methods further comprise contacting the cDNA with a template switch oligonucleotide comprising a universal PCR primer sequence, thereby generating a single stranded cDNA, and performing second strand synthesis on the single stranded cDNA, thereby producing a double stranded heavy chain and/or light chain cDNA. A heavy chain and/or light chain sequencing template is produced, and the methods further comprise sequencing the template by Sanger sequencing. Also provided are kits that find use, e.g., in practicing the methods of the present disclosure.

IPC Classes  ?

  • C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12Q 1/6869 - Methods for sequencing

90.

CONDUCTIVE POLYMER EMULSION

      
Application Number 16900556
Status Pending
Filing Date 2020-06-12
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Liu, Gao
  • Zheng, Tianyue

Abstract

The present invention provides for an emulsion comprising solid particles of a single composition, or a mixture thereof, comprising a polymer comprising one monomer of an aryl methacrylate, or a mixture thereof, co-polymerized with a monomer of an alkyl methacrylate, or a mixture thereof; wherein Ar is an aryl group and R is an alkyl group, and n:m has a ratio of from about 0:100 to about 100:0.

IPC Classes  ?

  • H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
  • C08F 220/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
  • C08J 3/07 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media from polymer solutions
  • H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
  • H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries

91.

SYSTEM AND METHOD FOR MEASURING SERUM PHOSPHATE LEVELS USING PORTABLE READER DEVICE

      
Application Number 16900838
Status Pending
Filing Date 2020-06-12
First Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ozcan, Aydogan
  • Ray, Aniruddha
  • Joung, Hyouarm
  • Tseng, Derek
  • Salusky, Isidro B.

Abstract

A portable colorimetric assay system includes an opto-mechanical reader configured to be detachably mounted to a mobile phone having a camera or other camera-containing portable electronic device. The opto-mechanical reader includes one or more light sources configured to illuminate a test sample holder and control sample holder disposed in the opto-mechanical reader along an optical path aligned with a camera of the mobile phone or other camera-containing portable electronic device. One or more serum separation membranes are disposed in the opto-mechanical reader and define a sample receiving pad configured to receive a blood sample. A moveable serum collection membrane is membrane is also disposed in the reader and is configured to contact the sample receiving pad in a first position and moveable to a second position where the serum collection membrane is disposed inside the test sample holder.

IPC Classes  ?

  • G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
  • G01N 21/25 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
  • G01N 33/49 - Physical analysis of biological material of liquid biological material blood
  • G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

92.

CABLE DRIVEN HYDRAULIC ROLLING DIAPHRAGM TRANSMISSION AND SERVO-SYSTEM

      
Application Number 16904468
Status Pending
Filing Date 2020-06-17
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Yip, Michael
  • Schreiber, Dimitri
  • Grant, Alex

Abstract

A linear to rotary motion converter includes a rigid body having first and second opposing end plates interconnected by at least one rigid crossmember. Each of the end plates is adapted to receive a rolling diaphragm linear actuator to thereby cause linear displacement of the rigid body in an axial direction upon actuation of the rolling diaphragm linear actuators. The linear to rotary motion converter also includes a capstan operably coupled to and located between the end plates such that linear motion of the rigid body caused by actuation of the rolling diaphragm linear actuators is translated to rotational motion of the capstan.

IPC Classes  ?

  • F16H 19/06 - Gearings comprising essentially only toothed gears or friction members and not capable of conveying indefinitely-continuing rotary motion for interconverting rotary motion and reciprocating motion comprising an endless flexible member
  • F15B 15/06 - Mechanical layout characterised by the means for converting the movement of the fluid-actuated element into movement of the finally-operated member for mechanically converting rectilinear movement into non-rectilinear movement

93.

ATHLETE STYLE RECOGNITION SYSTEM AND METHOD

      
Application Number 16904513
Status Pending
Filing Date 2020-06-17
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Bhanu, Bir
  • Liu, Hengyue
  • Li, Runze

Abstract

A system and method leverages understanding of complex dribbling video clips by representing a video sequence with a single Dribble Energy Image (DEI) that is informative for dribbling styles recognition. To overcome the shortage of labelled data, a dataset of soccer video clips employs Mask-RCNN to segment out dribbling players and OpenPose to obtain joints information of dribbling players. To solve issues caused by camera motions in highlight soccer videos, the system registers a video sequence to generate a single image representation DEI and dribbling styles classification.

IPC Classes  ?

  • G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
  • G06K 9/62 - Methods or arrangements for recognition using electronic means
  • G06N 3/08 - Learning methods
  • G06N 3/04 - Architecture, e.g. interconnection topology
  • A63B 67/00 - Sporting games or accessories therefor, not provided for in groups
  • A63B 69/00 - Training appliances or apparatus for special sports

94.

COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING NEUROINFLAMMATION, NEURODEGENERATION, NEUROPATHIC PAIN, AND MIGRAINE

      
Application Number 16909896
Status Pending
Filing Date 2020-06-23
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Miller, Yury
  • Yaksh, Tony L.

Abstract

In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia. In alternative embodiments, provided are methods comprising administering formulations and pharmaceutical compositions comprising an APOA1BP polypeptide or protein that is a human or a mammalian APOA1BP, or an AIBP1 or an AIBP2, or a recombinant, peptidomimetic or a synthetic APOA1BP, or a bioisostere of an ApoA-I Binding Protein to treat, ameliorate prevent, reverse, decrease the severity of a neuropathic pain, a TLR4-mediated allodynia and/or a hyperalgesia.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K 38/52 - Isomerases (5)
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
  • A61P 25/06 - Antimigraine agents
  • C07K 14/075 - Adenoviridae
  • C07K 14/775 - Apolipopeptides
  • C12N 9/90 - Isomerases (5.)
  • C12N 15/62 - DNA sequences coding for fusion proteins

95.

COOPERATIVE CHEMICAL ADSORPTION OF ACID GASES IN FUNCTIONALIZED METAL-ORGANIC FRAMEWORKS

      
Application Number 16912137
Status Pending
Filing Date 2020-06-25
First Publication Date 2020-12-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Long, Jeffrey R.
  • Mcdonald, Thomas M.

Abstract

A system and method for acid gas separations using porous frameworks of metal atoms coordinatively bound to polytopic linkers that are functionalized with basic nitrogen ligands that expose nitrogen atoms to the pore volumes forming adsorption sites. Adjacent basic nitrogen ligands on the metal-organic framework can form an ammonium from one ligand and a carbamate from the other. The formation of one ammonium carbamate pair influences the formation of ammonium carbamate on adjacent adsorption sites. Adsorption of acid gas at the adsorption sites form covalently linked aggregates of more than one ammonium carbamate ion pair. The acid gas adsorption isotherm can be tuned to match the step position with the partial pressure of acid gas in the gas mixture stream through manipulation of the metal-ligand bond strength by selection of the ligand, metal and polytopic linker materials.

IPC Classes  ?

  • B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
  • B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
  • B01D 53/40 - Acidic components
  • B01D 53/62 - Carbon oxides
  • B01J 20/30 - Processes for preparing, regenerating or reactivating
  • B01J 20/34 - Regenerating or reactivating
  • B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties

96.

SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES

      
Application Number 16912586
Status Pending
Filing Date 2020-06-25
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Griffiths, Leigh G.
  • Papalamprou, Angeliki
  • Wong, Maelene L.

Abstract

The present invention relates to methods for removing antigens from tissues by sequentially destabilizing and/or depolymerizing cytoskeletal components and removing and/or reducing water-soluble antigens and lipid-soluble antigens. The invention further relates to tissue scaffolding and decellularized extracellular matrix produced by such methods.

IPC Classes  ?

  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61K 35/34 - Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
  • C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
  • A61L 27/38 - Animal cells
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

97.

ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA

      
Application Number 17003153
Status Pending
Filing Date 2020-08-26
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Verkman, Alan S.
  • Tradtrantip, Lukmanee

Abstract

Provided herein is a method of treating neuromyelitis optica (NMO) in an animal or human subject comprising administering to the subject a composition comprising a therapeutically effective amount of an Fc region modified anti-AQP4 antibody, thereby treating the NMO in the subject. In some embodiments, the Fc region modified anti-AQP4 antibody is an anti-AQP4 antibody deglycosylated at the amino acid position Asn297. In other embodiments, the Fc region modified anti-AQP4 antibody is an anti-AQP4 antibody F(ab′)2 fragment.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

98.

Monitoring of Cell Expansion

      
Application Number 16441883
Status Pending
Filing Date 2019-06-14
First Publication Date 2020-12-17
Owner
  • GE Healthcare UK Limited (United Kingdom)
  • The Regents of the University of California (USA)
Inventor
  • Goodwin, Paul C.
  • Bowles, Paul A.
  • Gratch, Yarden S.
  • Iyer, Rohin K.
  • Davis, Cristina E.
  • Mccartney, Mitchell M.
  • Yamaguchi, Mei S.

Abstract

Disclosed is a method for monitoring cell density during cell expansion resulting from a cell culture process in a bioreactor comprising the steps of: a) cultivating cells in a bioreactor culture chamber according to a cell culture process having cell culture parameters; b) during said process, introducing cell culture fluid inputs and generating waste materials; c) determining the amount of volatile organic compounds (VOCs) and their chemical species in the waste materials; and d) estimating the density or population of cells in the bioreactor based on said determination.

IPC Classes  ?

  • C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
  • G01N 30/02 - Column chromatography
  • G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
  • G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12N 5/075 - Oocytes; Oogonia
  • G01N 33/483 - Physical analysis of biological material

99.

THERMOSTABLE RNA-GUIDED ENDONUCLEASES AND METHODS OF USE THEREOF

      
Application Number 16604946
Status Pending
Filing Date 2018-05-15
First Publication Date 2020-12-17
Owner The Regents of the University of California (USA)
Inventor
  • Kyrpides, Nikos C.
  • Doudna, Jennifer A.
  • Harrington, Lucas Benjamin
  • Paez-Espino, David

Abstract

The present disclosure provides RNA-guided endonucleases, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided endonuclease of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided endonuclease of the present disclosure and a guide RNA.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

100.

PROTEASE INHIBITORY ANTIBODIES AND METHODS OF USE THEREOF

      
Application Number 16880747
Status Pending
Filing Date 2020-05-21
First Publication Date 2020-12-17
Owner The Regents of The University of California (USA)
Inventor
  • Ge, Xin
  • Lopez, Tyler
  • Lee, Ki Baek

Abstract

Certain embodiments provide isolated anti-MMP-14 antibodies or fragments thereof, isolated anti-MMP-12 antibodies or fragments thereof, isolated anti-BACE-1 antibodies or fragments thereof, isolated anti-Alp2 antibodies or fragments thereof, and isolated anti-capthesin B antibodies or fragments thereof, as well as methods of use thereof.

IPC Classes  ?

  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  1     2     3     ...     80        Next Page